Developing next generation treatments to preserve vision for patients with diseases affecting the back of the eye

Latest news

Read or download our press releases for all latest news about our company, research & development activities and updates for investors. Consult our event calendar for an overview of conferences or meetings where you will be able to meet up with Oxurion associates. Be sure to check in regularly for the latest Oxurion press releases or just subscribe to our mailing list to receive regular updates.

Subscribe to our mailing list

25 Jun 2021
Company; THR-149; THR-687; Investors
Oxurion NV to Focus Resources on Clinical Assets THR-687 and THR-149

Leuven, BE, Boston, MA, US – June 25, 2021 – 07.00 AM CET – ...

10 Jun 2021
Company; THR-687
OXURION Confirms Institutional Review Board Approval and Submission of the Investigational New Drug Application to the FDA to Start Phase 2 Study Evaluating THR-687 for Diabetic Macular Edema (DME)

Leuven, BE, Boston, MA, US – June 10, 2021 – 07.00 AM CET –...

8 Jun 2021
THR-149; own
OXURION Completes Patient Enrollment for Part A of Phase 2 Study Evaluating THR-149 for Treatment of Diabetic Macular Edema (DME)

Leuven, BE, Boston, MA, US – June 8, 2021 – 07.00 AM CET –...

17 May 2021
Company
OXURION NV Appoints Tom Graney, CFA as Chief Executive Officer

Leuven, BE and Boston, MA, US – May 17, 2021 – 7:30 AM CET

...
30 Apr 2021
OXURION NV Presenting Scientific Data at ARVO 2021 Annual Meeting

Leuven, BE, Boston, MA, US – April 30st...

13 Apr 2021
Company; THR-149; THR-687; Investors
OXURION NV to Present at Wet AMD and DME Drug Development Summit

Leuven, BE, Boston, MA, US – April 13th, 2021 – 7.30 AM CET...

7 Apr 2021
THR-687
Oxurion NV – Publication in 'Progress in Retinal and Eye Research' highlights the potential of pan-RGD integrin antagonists to improve the treatment of diabetic retinopathy and wet AMD
 Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company developing next generation...

Archive

Media contact

Oxurion is committed and engaged to communicate openly with all of its stakeholders. For any media enquiries, comments or questions about Oxurion, please contact our Investor Relations & Corporate Communications team:

Wouter Piepers
Global Head of Corporate Communications and Investor Relations

Gaston Geenslaan 1
B-3001 Heverlee
Belgium
Tel: +32 16 751 310
Cell: +32 478 33 56 32
wouter.piepers@oxurion.com